CN111526877B - 用于ire1抑制的化合物和组合物 - Google Patents

用于ire1抑制的化合物和组合物 Download PDF

Info

Publication number
CN111526877B
CN111526877B CN201880066168.9A CN201880066168A CN111526877B CN 111526877 B CN111526877 B CN 111526877B CN 201880066168 A CN201880066168 A CN 201880066168A CN 111526877 B CN111526877 B CN 111526877B
Authority
CN
China
Prior art keywords
pyrazin
amino
imidazo
cyclohex
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880066168.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111526877A (zh
Inventor
R·M·基南
C·雷诺兹
B·惠特克
J·科耐特
J·萨顿
G·亨德
D·J·玛利
B·J·巴克斯
F·R·帕帕
S·A·奥克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opptikara Co
University of California San Diego UCSD
Original Assignee
Opptikara Co
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opptikara Co, University of California San Diego UCSD filed Critical Opptikara Co
Publication of CN111526877A publication Critical patent/CN111526877A/zh
Application granted granted Critical
Publication of CN111526877B publication Critical patent/CN111526877B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201880066168.9A 2017-09-01 2018-08-31 用于ire1抑制的化合物和组合物 Active CN111526877B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
US62/553,320 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (2)

Publication Number Publication Date
CN111526877A CN111526877A (zh) 2020-08-11
CN111526877B true CN111526877B (zh) 2023-08-25

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880066168.9A Active CN111526877B (zh) 2017-09-01 2018-08-31 用于ire1抑制的化合物和组合物

Country Status (13)

Country Link
US (1) US11649237B2 (enExample)
EP (1) EP3675858B1 (enExample)
JP (1) JP2020532589A (enExample)
KR (1) KR20200066301A (enExample)
CN (1) CN111526877B (enExample)
AU (1) AU2018326721B2 (enExample)
BR (1) BR112020004226A2 (enExample)
CA (1) CA3074139A1 (enExample)
IL (1) IL272845B2 (enExample)
MX (1) MX2020002322A (enExample)
SG (1) SG11202001609RA (enExample)
WO (1) WO2019046711A2 (enExample)
ZA (1) ZA202001320B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059841A1 (ja) * 2018-09-21 2020-03-26 国立大学法人 長崎大学 プリオン病治療薬
WO2020176765A1 (en) * 2019-02-27 2020-09-03 Optikira, LLC Pyrazolopyridine compounds for ire1 inhibition
CA3131386A1 (en) * 2019-02-27 2020-09-03 Richard Keenan Imidazolopyrazine compounds for ire1 inhibition
EP4192462A4 (en) * 2020-08-07 2024-09-04 Optikira LLC PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING THEM
EP4243815A4 (en) * 2020-11-13 2024-10-02 The Regents of the University of California IRE1ALPHA INHIBITORS AND USES THEREOF
JP2025504791A (ja) * 2022-01-07 2025-02-19 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル ヒドロキシフェニル部分を含む化合物及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064993A2 (en) * 2005-12-02 2007-06-07 Osi Pharmaceuticals, Inc. Bicyclic protein kinase inhibitors
CN103917545A (zh) * 2011-07-19 2014-07-09 默沙东公司 Btk抑制剂
CN104995192A (zh) * 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
ES2858328T3 (es) 2010-04-05 2021-09-30 Fosun Orinove Pharmatech Inc Inhibidores de IRE-1A
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
US10125123B2 (en) 2016-03-03 2018-11-13 Cornell University Small molecule IRE1-α inhibitors
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064993A2 (en) * 2005-12-02 2007-06-07 Osi Pharmaceuticals, Inc. Bicyclic protein kinase inhibitors
CN103917545A (zh) * 2011-07-19 2014-07-09 默沙东公司 Btk抑制剂
CN104995192A (zh) * 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
贾娴主编.《药物化学课堂笔记》.人民军医出版社,2011,(第1版),第9-13页. *

Also Published As

Publication number Publication date
IL272845B2 (en) 2023-12-01
BR112020004226A2 (pt) 2020-11-17
KR20200066301A (ko) 2020-06-09
CA3074139A1 (en) 2019-03-07
WO2019046711A3 (en) 2020-04-02
CN111526877A (zh) 2020-08-11
MX2020002322A (es) 2020-10-05
RU2020112425A3 (enExample) 2022-03-31
EP3675858A4 (en) 2021-03-17
AU2018326721B2 (en) 2022-12-01
RU2020112425A (ru) 2021-10-04
AU2018326721A1 (en) 2020-03-12
IL272845A (en) 2020-04-30
ZA202001320B (en) 2023-10-25
SG11202001609RA (en) 2020-03-30
WO2019046711A2 (en) 2019-03-07
US20200354367A1 (en) 2020-11-12
EP3675858A2 (en) 2020-07-08
IL272845B1 (en) 2023-08-01
US11649237B2 (en) 2023-05-16
EP3675858B1 (en) 2023-04-26
JP2020532589A (ja) 2020-11-12

Similar Documents

Publication Publication Date Title
CN111526877B (zh) 用于ire1抑制的化合物和组合物
CN112601750B (zh) Ptpn11（shp2）抑制剂
JP6949952B2 (ja) スピロ環化合物
CN119751456A (zh) 螺环化合物
US10870653B2 (en) WNT pathway modulators
AU2012345557A1 (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
KR101739003B1 (ko) 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
JPWO2019107386A1 (ja) 抗腫瘍剤
JP2019519534A (ja) 五員複素環［３，４−ｄ］ピリダジノン系化合物、その製造方法、医薬組成物及び応用
KR20250149802A (ko) Akt1의 공유결합 변형제 및 이의 용도
WO2017073743A1 (ja) 三環性化合物
TW202340166A (zh) 多環化合物
KR102636651B1 (ko) 티아졸로피리딘 또는 이의 약학적으로 허용 가능한 염 및 이의 용도
JP2024502106A (ja) ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるそれの使用
CA3181351A1 (en) Nampt modulators
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
WO2018204286A1 (en) An anti-cancer stemness drug
JP7175878B2 (ja) 新規ベンズイミダゾロン化合物およびその医薬用途
JP2023510135A (ja) 大環状化合物
WO2020176761A1 (en) Imidazolopyrazine compounds for ire1 inhibition
KR20250097910A (ko) 포스파티딜이노시톨 3-키나제의 신규 억제제
TW202313635A (zh) 巨環化合物
CN117715900A (zh) Srpk抑制剂
CN118019738A (zh) 作为sting拮抗剂的小分子脲衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant